CLSD vs. ANIX, IOBT, GNLX, ETON, QTTB, YS, PRPH, ANVS, MIST, and ASRT
Should you be buying Clearside Biomedical stock or one of its competitors? The main competitors of Clearside Biomedical include Anixa Biosciences (ANIX), IO Biotech (IOBT), Genelux (GNLX), Eton Pharmaceuticals (ETON), Q32 Bio (QTTB), YS Biopharma (YS), ProPhase Labs (PRPH), Annovis Bio (ANVS), Milestone Pharmaceuticals (MIST), and Assertio (ASRT). These companies are all part of the "pharmaceutical preparations" industry.
Clearside Biomedical (NASDAQ:CLSD) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, community ranking, analyst recommendations, valuation, risk and profitability.
18.8% of Clearside Biomedical shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 9.8% of Clearside Biomedical shares are owned by company insiders. Comparatively, 22.6% of Anixa Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Clearside Biomedical received 338 more outperform votes than Anixa Biosciences when rated by MarketBeat users. Likewise, 67.17% of users gave Clearside Biomedical an outperform vote while only 64.29% of users gave Anixa Biosciences an outperform vote.
Anixa Biosciences has lower revenue, but higher earnings than Clearside Biomedical. Anixa Biosciences is trading at a lower price-to-earnings ratio than Clearside Biomedical, indicating that it is currently the more affordable of the two stocks.
Clearside Biomedical has a beta of 2.35, meaning that its share price is 135% more volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.
Anixa Biosciences has a net margin of 0.00% compared to Clearside Biomedical's net margin of -413.73%. Clearside Biomedical's return on equity of 0.00% beat Anixa Biosciences' return on equity.
In the previous week, Clearside Biomedical had 17 more articles in the media than Anixa Biosciences. MarketBeat recorded 25 mentions for Clearside Biomedical and 8 mentions for Anixa Biosciences. Clearside Biomedical's average media sentiment score of 0.32 beat Anixa Biosciences' score of 0.16 indicating that Clearside Biomedical is being referred to more favorably in the media.
Clearside Biomedical presently has a consensus target price of $4.50, suggesting a potential upside of 240.91%. Anixa Biosciences has a consensus target price of $12.00, suggesting a potential upside of 309.56%. Given Anixa Biosciences' higher probable upside, analysts plainly believe Anixa Biosciences is more favorable than Clearside Biomedical.
Summary
Clearside Biomedical beats Anixa Biosciences on 9 of the 17 factors compared between the two stocks.
Get Clearside Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLSD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Clearside Biomedical Competitors List
Related Companies and Tools
